<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1038/s41420-019-0206-2</query><apiKey>6b19ee21fe6a243741a528650f7c8997</apiKey><result><total>1</total><start>1</start><pageLength>1</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><article dtd-version="1.2" article-type="research-article" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="publisher-id">41420</journal-id><journal-id journal-id-type="doi">10.1038/41420.2058-7716</journal-id><journal-title-group><journal-title>Cell Death Discovery</journal-title><abbrev-journal-title abbrev-type="publisher">Cell Death Discov.</abbrev-journal-title></journal-title-group><issn pub-type="epub">2058-7716</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s41420-019-0206-2</article-id><article-id pub-id-type="manuscript">206</article-id><article-id pub-id-type="doi">10.1038/s41420-019-0206-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="SubjectPath"><subject>/631/67/1504</subject></subj-group><subj-group subj-group-type="SubjectPath"><subject>/692/308/2778</subject></subj-group><subj-group subj-group-type="NatureArticleTypeID"><subject>article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Optineurin downregulation induces endoplasmic reticulum stress, chaperone-mediated autophagy, and apoptosis in pancreatic cancer cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="Au1"><name><surname>Ali</surname><given-names>Doaa M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au2"><name><surname>Ansari</surname><given-names>Shariq S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au3"><name><surname>Zepp</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au4"><name><surname>Knapp-Mohammady</surname><given-names>Michaela</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes" id="Au5"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3783-5365</contrib-id><name><surname>Berger</surname><given-names>Martin R.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="corresp" rid="IDs4142001902062_cor5">e</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0492 0584</institution-id><institution-id institution-id-type="GRID">grid.7497.d</institution-id><institution content-type="org-division">Toxicology and Chemotherapy Unit</institution><institution content-type="org-name">German Cancer Research Center</institution></institution-wrap><addr-line content-type="city">Heidelberg</addr-line><country country="DE">Germany</country></aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2260 6941</institution-id><institution-id institution-id-type="GRID">grid.7155.6</institution-id><institution content-type="org-division">Department of Pharmacology and Experimental Therapeutics, Medical Research Institute</institution><institution content-type="org-name">Alexandria University</institution></institution-wrap><addr-line content-type="city">Alexandria</addr-line><country country="EG">Egypt</country></aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0224 711X</institution-id><institution-id institution-id-type="GRID">grid.240871.8</institution-id><institution content-type="org-division">Cell and Molecular Biology</institution><institution content-type="org-name">St. Jude Children’s Research Hospital</institution></institution-wrap><addr-line content-type="city">Memphis</addr-line><addr-line content-type="state">TN</addr-line><country country="US">USA</country></aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0492 0584</institution-id><institution-id institution-id-type="GRID">grid.7497.d</institution-id><institution content-type="org-division">Division of Functional Genome Analysis</institution><institution content-type="org-name">German Cancer Research Center</institution></institution-wrap><addr-line content-type="city">Heidelberg</addr-line><country country="DE">Germany</country></aff></contrib-group><author-notes><corresp id="IDs4142001902062_cor5"><label>e</label><phone>+49 6221 42 3310</phone><email>m.berger@dkfz-heidelberg.de</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>9</day><month>8</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2019</year></pub-date><volume>5</volume><issue seq="76">1</issue><elocation-id>128</elocation-id><history><date date-type="registration"><day>19</day><month>7</month><year>2019</year></date><date date-type="received"><day>4</day><month>4</month><year>2019</year></date><date date-type="rev-recd"><day>28</day><month>6</month><year>2019</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2019</year></date><date date-type="online"><day>9</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>© The Author(s) 2019</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="url">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1" xml:lang="en"><title>Abstract</title><p id="Par1">Pancreatic ductal adenocarcinoma (PDAC) shows a high level of basal autophagy. Here we investigated the role of optineurin (OPTN) in PDAC cell lines, which is a prominent member of the autophagy system. To that purpose, mining of publically available databases showed that OPTN is highly expressed in PDAC and that high levels of expression are related to reduced survival. Therefore, the role of OPTN on proliferation, migration, and colony formation was investigated by transient knockdown in Miapaca, BXPC3, and Suit2-007 human PDAC cells. Furthermore, gene expression modulation in response to OPTN knockdown was assessed by microarray. The influence on cell cycle distribution and cell death signaling cascades was followed by FACS, assays for apoptosis, RT-PCR, and western blot. Finally, autophagy and ROS induction were screened by acridine orange and DCFH-DA fluorescent staining respectively. OPTN knockdown caused significant inhibition of colony formation, increased migration and no significant effect on proliferation in Miapaca, BXPC3 and Suit2-007 cells. The microarray showed modulation of 293 genes in Miapaca versus 302 in Suit2-007 cells, of which 52 genes overlapped. Activated common pathways included the ER stress response and chaperone-mediated autophagy, which was confirmed at mRNA and protein levels. Apoptosis was activated as shown by increased levels of cleaved PARP, Annexin V binding and nuclear fragmentation. OPTN knockdown caused no increased vacuole formation as assessed by acridine orange. Also, there was only marginally increased ROS production. Combination of OPTN knockdown with the autophagy inducer erufosine or LY294002, an inhibitor of autophagy, showed additive effects, which led us to hypothesize that they address different pathways. In conclusion, OPTN knockdown was related to activation of ER stress response and chaperone-mediated autophagy, which tend to confine the damage caused by OPTN knockdown and thus question its value for PDAC therapy.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution>Deutscher Akademischer Austauschdienst (German Academic Exchange Service)</institution><institution-id institution-id-type="doi" vocab="open-funder-registry">https://doi.org/10.13039/501100001655</institution-id></institution-wrap></funding-source><award-id award-type="FundRef grant">91541444</award-id><principal-award-recipient><name><surname>Ali</surname><given-names>Doaa M.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>Springer Nature</meta-value></custom-meta><custom-meta><meta-name>volume-issue-count</meta-name><meta-value>2</meta-value></custom-meta><custom-meta><meta-name>issue-article-count</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-pricelist-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-holder</meta-name><meta-value>The Author(s)</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-contains-esm</meta-name><meta-value>Yes</meta-value></custom-meta><custom-meta><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-month</meta-name><meta-value>7</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-day</meta-name><meta-value>19</meta-value></custom-meta><custom-meta><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>journal-product</meta-name><meta-value>NonStandardArchiveJournal</meta-value></custom-meta><custom-meta><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/41420_2019_Article_206.pdf</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>article-type</meta-name><meta-value>OriginalPaper</meta-value></custom-meta><custom-meta><meta-name>journal-subject-primary</meta-name><meta-value>Life Sciences</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Life Sciences, general</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Biochemistry, general</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Cell Biology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Stem Cells</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Apoptosis</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Cell Cycle Analysis</meta-value></custom-meta><custom-meta><meta-name>journal-subject-collection</meta-name><meta-value>Biomedical and Life Sciences</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="Misc"><p>Edited by M.V. Niklison Chirou</p></notes></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Optineurin (OPTN) is encoded by a gene on chromosome 10p13, which has 16 exons, 3 of which are noncoding. After translation the protein consists of 577 amino acids (Fig. <xref rid="Fig1" ref-type="fig">1a, b</xref>)<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>, has an apparent size of a 67 kDa, a half-life of ~8 h, and its turnover involves the ubiquitin proteasomal system<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. OPTN consists of several domains: a Nemo NF-κB-essential molecule -like domain, leucine zipper motif, an LC3-interacting region, coiled-coil motifs, an ubiquitin-binding domain, and a C-terminal C2H2 type zinc finger motif<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup> (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). OPTN interacts with itself to form homo-oligomers<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> as well as with other molecules including Ras-related protein 8 (Rab8)<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, huntingtin<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, myosin VI<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, transferrin receptor<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>, LC3/GABARAP<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>, polo-like kinase 1<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>, TANK binding kinase 1<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> as well as many others<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> (Fig. <xref rid="Fig1" ref-type="fig">1d</xref>). The conformation of certain parts of OPTN has been determined by X-ray analysis (Fig. <xref rid="Fig1" ref-type="fig">1e</xref>)<sup><xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR16">16</xref></sup>.<fig id="Fig1"><label>Fig. 1</label><caption xml:lang="en"><title>Structure of optineurin.</title><p>Graphic illustration of optineurin at genomic (<bold>a</bold>), mRNA (<bold>b</bold>), and protein levels (<bold>c</bold>, <bold>e</bold>). <bold>a</bold> The OPTN structure at genomic level was generated using the NCBI sequence (reference NG_012876.1 (<ext-link xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/257743476" ext-link-type="url">https://www.ncbi.nlm.nih.gov/nuccore/257743476</ext-link>)), and the scaling factors used were 1:400 bp (for exons) and 1:4000 bp (for introns). Together, 16 exons form the OPTN gene. <bold>b</bold> The mRNA was generated from the same source and consists of 1734 bp. <bold>c</bold> The protein contains various structural domains, and the localization of these domains is indicated relative to the amino acid sequence as well as to some interacting proteins (<bold>d</bold>). LZ Leucine-zipper domain, LIR LC3-interacting region, CC coiled coil domain, UBD ubiquitin-binding domain, ZF zinc finger domain, TBK tank binding kinase, Rab8 RAB8A, Member RAS Oncogene Family, LC3/GABARAP light chain 3/beta, GABA type A receptor associated protein. CYLD CYLD Lysine 63 Deubiquitinase, HTT huntingtin. <bold>e</bold> Crystal structure of different OPTN domains as determined by <italic>X</italic>-ray analysis. These images were made with VMD, which is owned by the theoretical and computational biophysics group, NIH Center for Macromolecular Modeling and Bioinformatics, at the Beckman Institute, University of Illinois at Urbana-Champaign. E.1<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> represents the structure of the amino acids 26–103 (HLAHP NLDTFTPEEL LQQMKELLTE NHQLKEAMKL NNQAMKGRFE ELSAWTEKQK EERQFFEIQS KEAKERLMAL SHE). E.2<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> represents OPTN amino acids from 170 to 181 or LC3B interacting region (the sequence consists of SGSSEDSFVE I). E.3<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> shows the crystal structure of UBD spanning the amino acids 416–510 (EKVDR AVLKELSEKL ELAEKALASK QLQMDEMKQ TIAKQEEDLE TMTILRAQME VYCSDFHAER AAREKIHEEK EQLALQL AVL LKENDAFEDG)</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41420_2019_206_Fig1_HTML.png"/></p></fig></p><p id="Par3">OPTN has several physiological roles including membrane trafficking, maintenance of the Golgi apparatus, exocytosis and protein secretion, cell division control, suppression of the NF-κB pathway, and host defense against pathogens<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>. Overexpression of OPTN was protective against H<sub>2</sub>O<sub>2</sub> mediated cell death<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par4">OPTN was identified as a selective autophagy receptor because it binds to polyubiquitinated cargoes and brings them to autophagosomes via its LC3-interacting region<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR20">20</xref></sup>. Thus, it can get rid of pathogens as salmonella<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, defective mitochondria<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, misfolded protein aggregates<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> or can have a role in tumor suppression<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. The role of OPTN in autophagy can be also independent from ubiquitination<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>.</p><p id="Par5">Beside all the physiological roles, mutations of OPTN or its altered expression are associated with multiple diseases, including normal tension glaucoma and primary open-angle glaucoma<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, as well as plenty of neurodegenerative diseases<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Diminished OPTN expression might increase the risk of developing Crohn’s disease<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> and predisposes to the occurrence of Paget’s disease by enhancing osteoclast differentiation, as OPTN was identified as a regulator of bone resorption<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Increased expression has been found in several cancers, including pancreatic cancer (for details see “Results” section).</p><p id="Par6">Pancreatic cancers are suspected to become the second leading cause of cancer-related deaths in the United States by the year of 2030<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of all diagnosed pancreatic cancers<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. PCAC has a poor prognosis with a mortality rate that is almost equal to the incidence rate and a 5-year survival rate of only 7% for all stages<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>.</p><p id="Par7">Surgery remains the only potentially curative treatment for nonmetastatic PDAC<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. Combination chemotherapy or targeted therapy cause only modest improvement in survival<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. This background is reason for modern strategies pending on new biomarker identification and patient selection<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>.</p><p id="Par8">The role of autophagy in PDAC is quite complex, with several studies indicating that autophagy has a tumor suppressive role and others reporting an onco-stimulatory effect<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. An exciting point about PDAC is that primary tumors and cell lines show elevated basal autophagy<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, yet the role of autophagy in PDAC is still to be clarified<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>.</p><p id="Par9">Here, we investigated the role of OPTN in PDAC cells. After transient knockdown, alterations in cellular properties were observed including proliferation, migration, and colony formation as well as induction of autophagy and apoptosis. Furthermore, OPTN expression of PDAC patients was used from the Human Protein Atlas database. Our results hint to OPTN as a versatile factor in the progression of cancer in general and of PDAC in particular.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Optineurin is overexpressed in pancreatic cancer</title><p id="Par10">For assessing the expression of OPTN in human cancers, publically available databases were explored. An overview of the RNA-seq data provided by The Cancer Genome Atlas (TCGA) revealed high expression of the OPTN gene across several tumor types (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>)<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>.<fig id="Fig2"><label>Fig. 2</label><caption xml:lang="en"><title>OPTN expression from publically available human cancer data.</title><p><bold>a</bold> Overview of the RNA-seq data in TCGA of 17 cancer cohorts showing the highest OPTN expression in renal cell carcinoma followed by PDAC (expressed in terms of median FPKM). <bold>b</bold> Kaplan–Meier curves of high and low OPTN expression in PDAC versus the survival of patients (log rank <italic>p</italic>-value (1.4e-2). Both <bold>a</bold> and <bold>b</bold> data were retrieved from human protein atlas (<ext-link xlink:href="https://www.proteinatlas.org/ENSG00000123240-OPTN/pathology/tissue/pancreatic+cancer" ext-link-type="url">https://www.proteinatlas.org/ENSG00000123240-OPTN/pathology/tissue/pancreatic+cancer</ext-link>). <bold>c</bold> Expression of autophagy related genes and receptors in the PDAC cell cohort with a sample size of 179 patients. The mean control expression is indicated by the straight line across all groups. All expression levels shown are &gt;7.5 log2 rsem (Rna-Seq by Expectation Maximization)</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41420_2019_206_Fig2_HTML.png"/></p></fig></p><p id="Par11">Remarkably, pancreatic cancer was associated with the second highest OPTN expression of all tumor tissues, superseded only by renal cancer, as shown in Fig. <xref rid="Fig2" ref-type="fig">2a</xref><sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. The median number of <underline>f</underline>ragments per kilobase of exon per million reads (FPKM) was 25 for pancreatic cancer. Increased OPTN expression was related to a significantly reduced survival probability of PDAC patients (<italic>P</italic> = 0.014; Fig. <xref rid="Fig2" ref-type="fig">2b</xref>)<sup><xref ref-type="bibr" rid="CR37">37</xref>–<xref ref-type="bibr" rid="CR39">39</xref></sup>.</p><p id="Par12">As the reported high expression could render OPTN an attractive target for therapy, we became interested in its function. OPTN is an autophagy receptor, the importance of which is substantiated by the observation that almost all members of the autophagy process show increased expression in PDAC (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>). As found from a TCGA cohort with a sample size of 179 PDAC patients, most of the autophagy genes show genomic expression above average, as indicated by &gt;7.5 log2 rsem (RNA-Seq by expectation maximization). Among these genes, OPTN showed the second highest expression superseded only by sequestosome 1(SQSTM1) (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>). Prompted by this information, we set out to discover the role of OPTN in PDAC using a panel of PDAC cell lines.</p></sec><sec id="Sec4"><title>Effect of OPTN knockdown on cellular functions</title><p id="Par13">Target specific siRNA (12.5 nM) knocked down OPTN expression successfully in three pancreatic cancer cell lines (Miapaca, Suit2-007 and BXPC3). The knockdown efficacy at mRNA level as tested by qRT-PCR (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>), was comparably high in all three cell lines ranging from 95% (BXPC3) to &gt;96% (Miapaca and Suit2-007).<fig id="Fig3"><label>Fig. 3</label><caption xml:lang="en"><title>Effect of OPTN knockdown on PDAC cellular functions.</title><p>The three columns represent results from BXPC3 (left), Miapaca (middle) and Suit2-007 (right). <bold>a</bold>, <bold>b</bold> mRNA and protein expression of OPTN in three pancreatic cell lines determined by qRT-PCR and WB at 48 h post siRNA transfection. All specific knockdown samples were compared with untreated and treated controls. Samples were normalized to GAPDH for qRT-PCR and to β-actin for WB. Calculation for qRT-PCR was done using the ΔΔCT method and imageJ was used to measure band densities for western blot. <bold>c</bold> Cytotoxic effect of OPTN silencing on three pancreatic cancer cell lines post transfection with the MTT assay. Absorbance was measured at 540 nm wavelength with a reference of 690 nm. <bold>d</bold> Migration assay showing the number of migrating cells following transfection using a transwell 2 compartment model that was determined by cell titer blue (Excitation 560/15 and Emission 590/ 20). The assays were done in triplicate and the results represent their average. <bold>e</bold> Colony formation assay was started at 48 h post transfection and shows the number of colonies as well as that of the nonspecific control after 7–10 days. The assay was done in quadruplicate and the data represent the respective average with standard deviation. Statistical analysis for all tests was done with Student’s <italic>t</italic>-test and one way Anova with <italic>p</italic> values ≤ 0.05 considered significant. *<italic>p</italic> &lt; 0.01, **<italic>p</italic> &lt; 0.001, ***<italic>p</italic> &lt; 0.0001</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41420_2019_206_Fig3_HTML.png"/></p></fig></p><p id="Par14">At protein level, as determined by western blot (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>), the knockdown efficiency ranged from 80% (Miapaca) to 70% (BXPC3) and 50% (Suit2-007). The subsequent experiments focused on the effect of OPTN knockdown on cellular functions.</p><p id="Par15">As shown in Fig. <xref rid="Fig3" ref-type="fig">3c</xref>, proliferation was not significantly altered by OPTN knockdown in the three cell lines. In partial contrast, migration was significantly increased in BXPC3 and Miapaca cells, but not significantly in Suit2-007 cells (Fig. <xref rid="Fig3" ref-type="fig">3d</xref>). The most striking effect was observed for colony formation (Fig. <xref rid="Fig3" ref-type="fig">3e</xref>), which was reduced to 32.5, 48, and 45% in Miapaca, BXPC3 and Suit2-007 cells, respectively, in comparison with siRNA<sup>control</sup> (100%).</p></sec><sec id="Sec5"><title>Modulation of genes in response to OPTN knockdown</title><p id="Par16">To possibly explain the changes in cellular functions following OPTN knockdown, a microarray was performed in two cell lines (Miapaca and Suit2-007). A cutoff (1.5-fold) was used for differentiating between significant and background changes in expression. The results were analyzed by Ingenuity Pathway Analysis (IPA) software and revealed 293 genes being significantly modulated in Miapaca compared with 304 genes in Suit2-007 cells. From these, 52 genes were significantly deregulated in both cell lines as shown by the Venn diagram (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). Overall 38 of these 52 genes were downregulated (e.g., CDK6: −2.38-fold in Miapaca and −1.76-fold in Suit2-007; CCNE1: −1.79-fold in Miapaca and −1.60-fold in Suit2-007; and protein arginine methyltransferase 6 (PRMT6): −2.47-fold in Miapaca and −1.76-fold in Suit2-007). In addition, 11 of 52 genes were upregulated (e.g., BCAT1: 1.7-fold in Miapaca and 1.5-fold in Suit2-007, claudin 1 (CLDN1): 1.95-fold in Miapaca and 1.85-fold in Suit2-007; and Lysosomal associated membrane protein 2 (LAMP2): 1.6-fold in both cell lines). Finally, three genes were differently modulated (e.g., interferon- induced transmembrane protein 3 (IFITM3): 1.5-fold in Miapaca and −1.713-fold in Suit2-007). All modulated genes are given in Supplementary Tables <xref ref-type="supplementary-material" rid="MOESM5">1</xref>–<xref ref-type="supplementary-material" rid="MOESM7">3</xref>.<fig id="Fig4"><label>Fig. 4</label><caption xml:lang="en"><title>Microarray data with modulation of genes in response to OPTN-KD.</title><p><bold>a</bold> The Venn diagram shows 52 genes modulated in both Miapaca and Suit2-007 cells, with 1.5-fold change taken as cutoff for analysis (detailed gene lists are shown in Supplementary tables <xref ref-type="supplementary-material" rid="MOESM5">1</xref>, <xref ref-type="supplementary-material" rid="MOESM6">2</xref>, <xref ref-type="supplementary-material" rid="MOESM7">3</xref>). <bold>b</bold> Heat map generated by IPA software showing 13 modulated canonical pathways, which are affected by the knockdown in either of the cell lines, with activation Z scores ranging from −2.8 to 2. <bold>c</bold> Cell cycle distribution of propidium iodide staining by flow cytometry in Miapaca cells, as calculated by flowing software. <bold>d</bold> The bar graph shows the distribution of Miapaca cells according to the cell cycle stages as calculated by flowing software and presented as % of cells. <bold>e</bold> qRT-PCR data showing the expression of cell cycle genes (CDK6, CDK4, CCND1, CCND3) following OPTN-KD in the three PDAC cell lines BXPC3, Miapaca and Suit2-007 in comparison with siRNA control as calculated by the ∆∆ CT method. <bold>f</bold> WB results of various CDKs in response to OPTN-KD in Miapaca cells. Analysis of the band density was done by ImageJ software and corrected to β-actin and to negative siRNA as control. <bold>g</bold> Heat map of the upper 30 common upstream regulators following OPTN-KD in Miapaca and Suit2-007 cells according to the activation <italic>Z</italic> score generated by IPA software</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41420_2019_206_Fig4_HTML.png"/></p></fig></p><p id="Par17">Canonical pathway analysis revealed the activation of phospholipase C and thrombin signaling in both cell lines. From the other 11 canonical pathways identified by IPA, the majority was altered in Miapaca cells, only (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>).</p><p id="Par18">For validating the effect on cell cycle in Miapaca cells, the DNA distribution was analyzed by flow cytometry. As shown in Fig. <xref rid="Fig4" ref-type="fig">4c</xref>, there were moderate reductions in cells undergoing G1 and G2/M phases, and a mild increase in S phase cells (Fig. <xref rid="Fig4" ref-type="fig">4c, d</xref>). The pre-G1 (subG1) fraction, as an indicator of cell death, was increased in OPTN knockdown samples with a percentage of 12.7% compared with 2.7% in the siRNA<sup>control</sup> when analyzed by flowing software. These observations correlate with reduced expression of CDK6 mRNA in all three cell lines (Fig. <xref rid="Fig4" ref-type="fig">4e</xref>), and of CDK6 protein in Miapaca cells (Fig. <xref rid="Fig4" ref-type="fig">4f</xref>). Concomitantly, a less prominent reduction of CDK4 at mRNA and protein levels was observed. For cyclins, a less uniform modulation was observed, as cyclin D1 was increased in Miapaca (mRNA and protein) and Suit2-007 cells (mRNA), but decreased in BXPC3 cells (mRNA). Similarly, cyclin D3 was increased in Miapaca, but slightly decreased in Suit2-007 and BXPC3 cells (mRNA). Furthermore, p27 was increased in Miapaca cells at protein level in response to OPTN knockdown (Fig. <xref rid="Fig4" ref-type="fig">4f</xref>).</p><p id="Par19">Analysis of upstream regulators showed matching upregulation of activating transcription factor 4 (ATF4), nuclear protein 1, uncoupling protein 1, Combgap, KRAS Proto-Oncogene-GTPase (KRAS), claudin 7, platelet derived growth factor B, and NK2 Homeobox 3. All other upstream regulators showed divergent results between the two cell lines (Fig. <xref rid="Fig4" ref-type="fig">4g</xref>).</p></sec><sec id="Sec6"><title>OPTN knockdown activates ER stress and chaperone-mediated autophagy</title><p id="Par20">As ATF4 was found among the highly modulated upstream regulators of OPTN, the related network was studied more closely. This analysis showed activation of several ATF4 network genes, which, however, differed in modulation between the two cell lines, except for ASNS and branched chain amino acid transaminase 1 (BCAT1) (Fig. <xref rid="Fig5" ref-type="fig">5a</xref>). Interestingly, at mRNA level, ATF4 was upregulated only in Miapaca cells; however, at protein level, it was distinctly higher expressed in Suit2-007 than in Miapaca cells (3.3 vs. 1.4-fold; Fig. <xref rid="Fig5" ref-type="fig">5b</xref>). Other proteins of the ER stress response, as phosphorylated and unphosphorylated eIF2α and pPERK echoed this relationship, except for ATF6α, which was higher expressed in Miapaca than in Suit2-007 cells. The differential activation of the ER pathway at mRNA and protein levels was associated, however, with a highly similar activation of apoptosis, as indicated by the cleaved PARP levels (Fig. <xref rid="Fig5" ref-type="fig">5b</xref>). In line with PARP cleavage, staining of the Miapaca cells with Annexin V-FITC showed a higher population of early and late dead cells (Fig. <xref rid="Fig5" ref-type="fig">5c</xref>), while staining with Hoechst dye revealed nuclear fragmentation and shrinkage following OPTN knockdown (Fig. <xref rid="Fig5" ref-type="fig">5d</xref>). Staining of Suit2-007 and BXPC3 nuclei with Hoechst dye showed similar changes regarding fragmentation and shrinkage (Supplementary Fig. <xref ref-type="supplementary-material" rid="MOESM1">1A</xref>). Annexin V-FITC staining of Suit2-007 and BXPC3 cells showed a mild increase in the number of apoptotic and necrotic cells in knockdown samples when compared with siRNA control (Supplementary Fig. <xref ref-type="supplementary-material" rid="MOESM1">1B</xref>).<fig id="Fig5"><label>Fig. 5</label><caption xml:lang="en"><title>OPTN knockdown causes activation of ATF4 and other members of the ER stress-signaling pathway, chaperone-mediated autophagy and apoptosis.</title><p><bold>a</bold> Heat map of genes in the ATF4 network (IPA software) for Miapaca and Suit2-007 cells with the respective fold changes in expression. <bold>b</bold> WB analysis of the different antibodies in the ER stress-signaling pathway including pEIF2α, ATF6, pPERK and ATF4 as well as cleaved PARP. <bold>c</bold> Miapaca cells stained with Annexin V-FITC show increased numbers of apoptotic cells in the OPTN KD sample as compared with nonspecific control and as detected from the percentage of gated cells in the lower right quadrant. <bold>d</bold> Staining of Miapaca cells with Hoechst 33248 stain 48 h following transfection with siRNA. OPTN samples show nuclear abnormalities in terms of shrinkage and fragmentation. <bold>e</bold> Analysis of the expression of HSP90 and LAMP2 as regulators of chaperone-mediated autophagy (CMA) by immunoblotting 48 h post transfection with siRNA. Analysis of the band density was done by ImageJ software and corrected to β-actin as loading control and to negative siRNA as the main control</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41420_2019_206_Fig5_HTML.png"/></p></fig></p><p id="Par21">In addition, OPTN knockdown caused modulation of autophagy controlling genes. As revealed by microarray, several heat shock proteins (HSPE1, HSPA1A/HSPA1B and HSP90AB1) showed downregulation, and LAMP2, a main player in chaperone-mediated autophagy, was upregulated (Supplementary Table <xref ref-type="supplementary-material" rid="MOESM6">2</xref>). These data were confirmed at protein level for total HSP90 and LAMP2 in all three cell lines (Fig. <xref rid="Fig5" ref-type="fig">5e</xref>).</p><p id="Par22">For detecting autophagy in a cellular assay, acridine orange was used to visualize changes in the frequency of acidic vacuoles. However, no clear differences were observed between control and OPTN knockdown PDAC cells (Supplementary Fig. <xref ref-type="supplementary-material" rid="MOESM2">2A, B</xref>). Furthermore, a DCFH-DA-based flow cytometric analysis was used to check for reactive oxygen species (ROS) production. In BXPC3 and Miapaca cells, this method revealed a minute increase in ROS production when comparing siRNA<sup>OPTN</sup> versus siRNA<sup>control</sup> exposure. However, no effect was detected in Suit2-007 cells (Supplementary Fig. <xref ref-type="supplementary-material" rid="MOESM3">3</xref>).</p></sec><sec id="Sec7"><title>Drugs alter the expression of OPTN</title><p id="Par23">As OPTN knockdown influences genes involved in autophagy and apoptosis, two drugs were selected, which affect these cellular processes. Exposure of Miapaca and Suit2-007 cells to erufosine and LY294002, which differently influence autophagy, was followed at mRNA and protein levels as well as for their effect on proliferation. Erufosine caused concentration dependently increased mRNA transcription of OPTN, which was less prominent in Miapaca than in Suit2-007 cells. A similar increase was seen for mRNA levels of LC3B, which, however, were lower in Suit2-007 than in Miapaca cells (Fig. <xref rid="Fig6" ref-type="fig">6a</xref>). LY294002-induced concentration dependently increased mRNA transcription of OPTN, which was more distinct in Miapaca than in Suit2-007 cells, but LC3B mRNA levels were not significantly increased in Miapaca and even decreased in Suit2-007 cells (Fig. <xref rid="Fig6" ref-type="fig">6a</xref>). At protein level, erufosine caused a 40% reduction of OPTN levels in Miapaca but a 1.6-fold increase in Suit2-007 cells. Concomitantly, the concentrations of LC3B were increased in both cell lines (Fig. <xref rid="Fig6" ref-type="fig">6b</xref>). LY294002 caused a uniform increase of OPTN in both cell lines, but no effect (Miapaca) and a slight reduction (Suit2-007) in LC3B levels (Fig. <xref rid="Fig6" ref-type="fig">6c</xref>). Both drugs caused an antiproliferative effect in the PDAC cell lines. The effect of erufosine was more pronounced in Miapaca than in Suit2-007 cells; whereas that of LY294002 was higher in Suit2-007 than in Miapaca cells (Fig. <xref rid="Fig6" ref-type="fig">6d</xref>). In combination with OPTN knockdown, however, erufosine exposure of Miapaca and Suit2-007 cells caused no additional decrease in OPTN mRNA or protein levels compared with OPTN knockdown alone (Supplementary Fig. <xref ref-type="supplementary-material" rid="MOESM4">4A, B</xref>). Equivalent results were observed for the combination of OPTN knockdown and exposure to LY294002 (Supplementary Fig. <xref ref-type="supplementary-material" rid="MOESM4">4A, C</xref>). For LC3B, there was no significantly increased concentration at mRNA and protein levels when OPTN knockdown was combined with either erufosine or LY294002 (Supplementary Fig. <xref ref-type="supplementary-material" rid="MOESM4">4A, D</xref>).<fig id="Fig6"><label>Fig. 6</label><caption xml:lang="en"><title>Effect of drugs on the expression of OPTN.</title><p><bold>a</bold> mRNA expression of OPTN and LC3B in the two pancreatic cell lines Miapaca and Suit2-007, as determined by qRT-PCR at 48 h post siRNA transfection. All specific knockdown samples were compared with corresponding controls (untreated cells as a control of erufosine and the DMSO (vehicle) treated cells in case of LY294002). Samples were normalized to GAPDH for qRT-PCR. Calculation for qRT-PCR was done using the ΔΔCT method. Statistical analysis for all tests was done by two-way Anova with significance considered for <italic>p</italic> values ≤ 0.05; significance is shown by an asterisk over the corresponding bar. <bold>b</bold> WB of Miapaca and Suit2-007 cells treated with different concentrations of the autophagy inducer erufosine 1 day following transfection with specific or nonspecific siRNA for OPTN. A total of 10–30 μg of protein were loaded per sample and the OPTN and LC3b expression levels were assessed. <bold>c</bold> WB of Miapaca and Suit2-007 cells treated with the autophagy inhibitor LY294002; shown are the expression of OPTN and the autophagy marker LC3B. <bold>d</bold> MTT assay of erufosine and LY294002 on cell survival (absorbance 540/690)</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41420_2019_206_Fig6_HTML.png"/></p></fig></p><p id="Par24">The observed additive interaction effects were confirmed by respective studies on the proliferation of Miapaca and Suit2-007 cells in response to erufosine, LY294002, or knockdown of OPTN alone, or combination of OPTN knockdown with either erufosine or LY294002 exposure (Supplementary Fig. <xref ref-type="supplementary-material" rid="MOESM4">4E</xref>).</p></sec></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p id="Par25">Physiologically, OPTN has a function as autophagy receptor and its presence stimulates autophagy<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. In addition, OPTN is known for its role in neurodegenerative diseases as amyotrophic lateral sclerosis and open angle glaucoma<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Interestingly, autophagy plays a role in neurodegenerative diseases as well as in cancer<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Based on publically available data we found that OPTN is highly expressed in cohort studies of 17 cancer types, with the highest expression in renal followed by pancreatic cancer, and the lowest expression detected in prostate cancer<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. In addition, when mining TCGA, OPTN was the second most expressed gene in PDAC from all autophagy related genes. Thus, we investigated the role of OPTN in PDAC, a cancer with almost identical incidence and mortality rates.</p><p id="Par26">In this first study on the role of OPTN in experimental pancreatic cancer, it was tempting to reduce OPTN levels, which are generally increased in PDAC, by a knockdown strategy in order to investigate its value as therapeutic target. Following successful knockdown in three PDAC cell lines, changes in cancer growth related cellular properties were recorded. They were used as surrogate for a response of PDAC in vivo. In addition, changes in gene expression caused by OPTN knockdown were recorded by a microarray.</p><p id="Par27">The knockout of other autophagy genes as ATG5 was associated with increased proliferation, migration and colony formation in mouse embryonic fibroblast and NIH 3T3 cells<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. In contrast, knockdown of OPTN had a minor and nonsignificant effect on the proliferation of pancreatic cancer cells, caused slightly but significantly increased migration in two of three PDAC cell lines and decreased colony formation distinctly in all three pancreatic cancer cell lines when compared with nonspecific siRNA control.</p><p id="Par28">In order to understand the mechanisms that govern these alterations, a microarray was performed in two PDAC cell lines after transient OPTN knockdown to obtain a comprehensive analysis of related mRNA expression changes. With regard to genes, which were modulated significantly in both cell lines (<italic>n</italic> = 52), 11 genes were found to be related to cell movement and motility. In addition, 2 of these 11 genes were related also to colony formation. From these 11 genes, 4 are known for their relationship to cancer progression: they include BCAT1, which was more than 1.5-fold upregulated in both cell lines. Interestingly, knockdown of BCAT1 was associated with reduced migration of nasopharyngeal and ovarian cancer cells<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. Another gene was CLDN1, which was upregulated more than 1.8-fold in both cell lines. CLDN1 is a member of the tight junction family of genes and has attracted attention because of its altered expression in many cancers as well as its association with cellular properties (invasion, migration) indicating cancer progression, which are normalized upon its knockdown in breast and lung cancer cells<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>. Further, PRMT6 was downregulated more than 1.7-fold in both cell lines. PRMT6 knockdown reduced the number of colonies in U2OS osteosarcoma cells<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> as well as in ZR75 and MCF7 breast cancer cells overexpressing proline-, glutamic acid-, and leucine-rich protein 1<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. Moreover, PRMT6 was found to regulate embryonic stem cell identity by modulating pluripotency genes and inducing expression of differentiation markers<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. In contrast, overexpression of PRMT6 was associated with reduced colony formation in breast and prostate cancer cells<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Finally, IFITM3 was 1.5-fold upregulated in Miapaca and 1.7-fold downregulated in Suit2-007 cells. IFITM3 is known as part of the cellular defense against influenza infection, but also plays a role in cancer progression as its knockdown suppressed migration and invasion in gastric cancer cells<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>.</p><p id="Par29">In addition to these functions influencing cell behavior, the microarray on PDAC cells with OPTN knockdown revealed induction of ER stress and chaperone-mediated autophagy. The activation of these cellular systems could be interpreted as adaptive mechanisms elicited in response to OPTN knockdown. In this perception (see Fig. <xref rid="Fig7" ref-type="fig">7</xref>), OPTN knockdown causes inhibition of autophagy. The PDAC cells, however, try to overcome this situation by releasing ER stress, as indicated by increased ATF4 levels and related signaling molecules including pPERK, (p) eIF2α and ATF6. The central role of ATF4 in ER stress and in inducing autophagy in response to hypoxic conditions has been well documented<sup><xref ref-type="bibr" rid="CR52">52</xref>–<xref ref-type="bibr" rid="CR54">54</xref></sup>. ROS contribute to autophagy induction<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>.<fig id="Fig7"><label>Fig. 7</label><caption xml:lang="en"><title>Scheme of the response of PDAC cells following OPTN KD.</title><p>OPTN knockdown triggered inhibition of autophagy and caused increased migration and reduced colony formation. PDAC cells tried to reverse autophagy inhibition by activating different pathways; i.e., by ER stress as indicated by activation of the PERK/EIF2-α /ATF4 pathway, by stimulating CMA as manifested by upregulation of LAMP2, and by a low increase in ROS production. Cells which could not reverse the consequences of OPTN knockdown underwent apoptosis</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41420_2019_206_Fig7_HTML.png"/></p></fig></p><p id="Par30">Further, heat shock proteins HSP90AB1, HSPA1A/HSPA1B, HSPE1 were downregulated following knockdown of OPTN. HSP90 has a regulatory role in the chaperone complex transferring damaged and misfolded proteins to the lysosome for chaperone-mediated autophagic (CMA) degradation. CMA is another form of autophagy, where proteins are transported directly from cytosol to the lysosomal lumen via interactions with chaperones located in their membrane and via a protein translocation complex<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. The concomitant reduction of HSP70 levels presumably further weakens the chaperone complex, which plays a central role through its capability to recognize the amino acid consensus sequence of misfolded and damaged proteins<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. LAMP2 was twofold upregulated following OPTN knockdown. This protein is the docking station for HSP70 and imports proteins tagged for degradation into the lysosomes. It is conceivable that the twofold increased expression at mRNA and protein levels was triggered by the diminished chaperone complex. In addition, ER stress may be responsible for LAMP2 induction<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. Apart from the role of HSP90 in CMA, specific inhibitors of HSP90, as geldanamycin, may induce autophagy<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>.</p><p id="Par31">Apoptosis was found to be upregulated in all cell lines in response to OPTN knockdown as proven by increased cleaved PARP expression, fragmentation of the nuclei by DAPI staining and increased Annexin V binding in respective pancreatic cancer cells. In this context, autophagy inhibition was found to induce apoptosis through P53 and ER stress<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. Li et al. demonstrated that withaferin A, a biologically active extract, induced ER stress mediated apoptosis through inhibition of lysosomal autophagic and proteosomal degradation<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. Another study revealed a switch that decreases apoptosis in favor of protective autophagy in methotrexate-resistant choriocarcinoma cells. This change was indicated by ER stress through the PERK/ATF4 pathway, or by ROS production through JNK/p62 signals<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>, which are both capable to induce autophagy.</p><p id="Par32">Owing to these rescue mechanisms that counteract autophagic inhibition and restore autophagy back to basal levels, we did not find many cellular effects that could be related to autophagy. Any of these mild effects found in response to OPTN knockdown were more pronounced in Miapaca than in Suit2-007 cells. The sub lying reason could be that Suit2-007 cells have undergone more mutations than Miapaca cells and therefore show less dependency on internal signaling. The effect on different pancreatic cellular functions following OPTN-KD was mild. The most important changes following knockdown are summarized in Fig. <xref rid="Fig7" ref-type="fig">7</xref>.</p><p id="Par33">Contrasting with the mild changes related to autophagy, the cell cycle was clearly changed in Miapaca cells in response to OPTN knockdown. In line with the altered G1/S and G2/M checkpoint regulation described by our IPA analysis, there were increased levels of p27, which in conjunction with reduced CDK6 levels caused an increase in non-phosphorylated cyclin D1. Concomitantly, there were reduced percentages of G2/M and post G2/M phases, as the cell cycle did not move further after reaching the S phase. In this scenario, the reduction observed for the G1 phase corresponds to the increase seen for the Pre-G1 phase as these cells probably underwent apoptosis.</p><p id="Par34">Although OPTN is part of the autophagy system, autophagy was only mildly affected in response to OPTN knockdown. This was surprising because a decreased OPTN level was expected to be in imbalance with cellular LC3 levels, for which OPTN has a binding site (Fig. <xref rid="Fig1" ref-type="fig">1c, d</xref>). We thus speculate that other autophagy receptors as e.g., SQSTM1/p62 took over and replaced the function of OPTN. Therefore, two drugs were used, which modulate autophagy in a reverse manner.</p><p id="Par35">LY294002 is a well-known inhibitor of phosphatidylinositol 3-kinase (PI3K) that acts on the ATP binding site of the enzyme<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. It was chosen as PI3K is required for autophagy and inhibition of PI3K with LY294002 can inhibit autophagic sequestration<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. Erufosine, on the other hand, is a potent inhibitor of mTOR and inducer of LC3B<sup><xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR65">65</xref></sup>. As expected, erufosine increased the expression of LC3B in both cell lines, whereas LY294002 caused no or a depressive effect on this indicator of autophagy<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. However, both drugs were largely ineffective in reversing the knockdown caused by siRNA against OPTN. Further, we had anticipated that the upregulation of LC3B by erufosine would enlarge the imbalance between OPTN and LC3B. However, the erufosine effect on LC3B levels was not antagonized by OPTN knockdown, indicating that the two autophagy proteins are regulated differently. Taken together, the influence of the two drugs on LC3B was not paralleled by their influence on OPTN and in combination with OPTN knockdown, the two drugs caused additive interactions; hence it is plausible that the two drugs and OPTN knockdown serve different pathways.</p><p id="Par36">The autophagy receptor OPTN is highly expressed in many human cancers including pancreatic cancer. Its knockdown in a panel of PDAC cells was related to mildly increased migration and distinctly reduced colony formation. In response to its knockdown, different rescue mechanisms became active; namely ER stress response and chaperone-mediated autophagy. These mechanisms reduce the potential damage caused by the gene’s knockdown. Finally, OPTN knockdown probably influences pathways different from those of erufosine and LY294002 in modulating autophagy.</p></sec><sec id="Sec9" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec10"><title>Cell lines and cell culture condition</title><p id="Par37">Three human pancreatic adenocarcinoma cell lines were cultured in RPMI-1640 (BXPC3, Suit2-007) and DMEM (Miapaca) medium (Invitrogen and Sigma Aldrich, Germany respectively). All media were supplemented with 10% fetal bovine serum and L-glutamine (2 mM), penicillin (100 IU/ml) and streptomycin (100 μg/ml) (Invitrogen, Karlsruhe, Germany). The cells were passaged routinely using 0.25% Trypsin/EDTA solution and maintained under standard incubation conditions (5% CO<sub>2</sub>, 37 °C) in a humidified atmosphere. Cell lines were authenticated using Multiplex Cell Authentication by Multiplexion (Heidelberg, Germany) as described recently<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. The SNP profiles matched known profiles or were unique.</p></sec><sec id="Sec11"><title>Small interfering RNA (siRNA) experiments</title><p id="Par38">Human OPTN siRNA (siRNA<sup>OPTN</sup>) was purchased (Invitrogen, Germany). siRNA seq (5′- 3′) sense: GGA AGU UUA CUG UUC UGA U (dT) (dT); antisense: AUC AGA ACA GUA AAC UUC C (dT) (dT)). AllStars siRNA serving as a non-targeting siRNA control was purchased from Qiagen, Germany. Cells were seeded at pre-optimized cell density in a six-well plate (8–10 × 10<sup>4</sup>/2000 μl), 24 h later siRNA was added in OptiMEM media to a final concentration of 12.5 nM using lipofectamine RNAimax (Invitrogen, Germany) as a transfection agent. Cells were incubated for 48 h under standard conditions until start of subsequent experiments.</p></sec><sec id="Sec12"><title>Cell viability assay</title><p id="Par39">Viability of selected cell lines, following knockdown by siRNA<sup>OPTN</sup> and siRNA<sup>control</sup>, or after treatment with erufosine (gift from Prof. H. Eibl, Max Planck-Institute of Biophysical Chemistry, Goettingen, Germany) or LY294002 (Cayman Chemical, USA) was tested by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide) assay as described before<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>.</p></sec><sec id="Sec13"><title>Migration assay</title><p id="Par40">The migratory behavior of pretreated pancreatic cancer cells by siRNA was studied by seeding cells in a 2 compartment model separated by 8 μm pore size polycarbonate membranes (Millicell, Millipore, Schwalbach, Germany) in a 24-well plate.</p><p id="Par41">The bottom layer of the plate consisted of 700-μl media with 20% FCS. Then, tumor cells (0.5–1 × 10<sup>5</sup> cells/300 μl optiMEM media) were seeded in the upper compartment. After 48 h, cell titer blue (Promega Gmbh, Mannheim, Germany) was added into the lower compartment (140 µl) at a ratio of 1/5 of the total amount of media contained. Fluorescence emitted by migrating viable cells due to their ability to reduce the dye Resazurin into the fluorescent pink dye Resorufin was estimated using a fluorometer at wavelengths (560/20) for excitation and 590/10) for emission.</p></sec><sec id="Sec14"><title>Colony formation assay (CFA)</title><p id="Par42">The cells were treated for 48 h, harvested and counted. Cells were then transferred into semi-solid medium containing 0.8% methylcellulose (MC) and 40% FCS, and plated onto 24-well plates (0.4 ml/well, with a final number of 100, 250, and 500 cells for Suit2-007, Miapaca, and BXPC3, respectively). These were incubated under usual cell culture conditions (37 °C, 5% CO2 in humidified air) and colonies were counted under the microscope after 7–10 days. Clusters of ≥10 cells were counted as colony. Data were represented as a percentage of the untreated control colony forming units (CFU).</p></sec><sec id="Sec15"><title>Cell cycle assay</title><p id="Par43">The distribution of DNA following knockdown was assessed using Propidium iodide staining and flow cytometry. Shortly, treated cells were harvested and resuspended in 0.1 ml of PBS (≈2 × 10<sup>5</sup> cells) after 48 h followed by the addition of 1.4 ml ice-cold ethanol (70%)/sample for fixation. The cells were incubated for 2 h at 4 °C, then washed, resuspended in PBS containing RNase A (1 mg/ml) for digesting any contaminating RNA and incubated for 30 min at 37 °C. Subsequently, PI (50 µg/ml) was added to the cells, and analysis was done immediately using a FACS Calibur (BD Biosciences, San Jose, CA, USA). Ten thousand cells (events) were analyzed from each sample, and the cell’s distributions in G0/G1, S and G2/M phases of cell cycle were calculated by flowing software.</p></sec><sec id="Sec16"><title>RNA isolation and cDNA synthesis</title><p id="Par44">After 48 h of exposure, the treated cells were harvested and washed; total RNA was extracted from the cell pellets with RNeasy Mini Kit (Qiagen, Hilden, Germany) following the manufacturer’s protocol. Concentrations of the extracted RNA were measured using a Nanodrop spectrophotometer (Nanodrop Technologies, Germany), and 1000 ng RNA was used to synthesize complementary DNA (cDNA) by using reverse transcriptase (Revertaid enzyme, Thermo Scientific, Schwerte, Germany). The cDNA samples were used as a template for further real-time PCR amplification and analysis.</p></sec><sec id="Sec17"><title>Quantitative real-time RT-PCR</title><p id="Par45">Modulation of OPTN expression (for primers and probes used, see Supplemantary Table <xref ref-type="supplementary-material" rid="MOESM8">4</xref>) following gene knockdown with siRNA was investigated by qRT-PCR. Briefly, 5 μl of LC480 2X Master Mix (Roche, Mannheim, Germany) was used in the amplification procedure of the cDNA sample, with 0.2 μl of each of the primers, 0.1 μl of the appropriate probe from the Human Universal Probe library (Roche, Mannheim, Germany) and 2.5 μl of water per reaction and 2 μl of the cDNA. The mixture was added into 384-well plates with a total volume of 10 μl/well. Each sample was represented in triplicate. GAPDH was used as reference gene in the normalization process of the corresponding sample. Corresponding changes in the expression levels of selected genes were calculated by 2<sup>ΔΔCT</sup> method.</p></sec><sec id="Sec18"><title>Western blot analysis</title><p id="Par46">At 48 h following treatment of pancreatic cancer cells by siRNA, erufosine or LY294002, the cells were harvested from six-well plates and washed with PBS. The cell pellets were thoroughly suspended in an adequate volume of lysis buffer consisting of RIPA buffer, complete protease inhibitor cocktail tablets (Roche, Mannheim, Germany), phosphostop tablets, and sodium vanadate. The samples were kept under constant agitation for 30 min at 4 °C, then centrifuged for 20 min (14000 rpm, 4 °C). Afterward, the supernatants were collected and the protein concentration was estimated using the Pierce Protein Assay. The calculated total protein lysates (20–30 μg) were added together with a DTT detergent and 4X dye to be denatured for 5 min (99 °C, 350 rpm) and thereafter were subjected to electrophoresis process using a 4–12% gradient polyacrylamide SDS gels in a 1X Laemmli running buffer. Transfer of proteins to PVDF membranes was done using a wet blotting system. The membranes were subject of test for several proteins using specific primary antibodies: OPTN (c2) (sc-166576, G2315), OPTN (D2L8S) (cs- 58981 S), ATF4 (sc-2280), ATF6 (sc-22799), cdk6 (cs-3136), cdk4 (cs-12790), cdk1 (Ab-133327), EIF2-α (cs-9722), pEIF2-α (cs-9721), pPERK(sc-32577), LAMP2 (cs-49067S), LC3B (cs-2775S), HSP90 (C45G5) (cs-4877), P27 kip (cs-2552), Cyclin D1 (cs-2978), cleaved PARP (cs-9541s), β-actin; mouse monoclonal antibody (sc-47778), and β-actin; goat polyclonal antibody (sc-1615). A corresponding secondary antibody was added and then the immunoblots were developed using an ECL-system (Amersham Pharmacia Biotech, Munich, Germany). Relative concentrations to β-actin, which was used as the loading control for whole cell lysates, were evaluated by densitometric analysis of images using the ImageJ software.</p></sec><sec id="Sec19"><title>Microarray analysis</title><p id="Par47">Total RNA was eluted in Rnase free water. The microarray was performed by the genomics and proteomics core facility in the DKFZ using Illumina Human HT-12 v4 Expression BeadChip Kits. Analysis of omic-data was done using the IPA software after the application of a cutoff of 1.5-fold change with comparison of knockdown samples with siRNA negative control.</p></sec><sec id="Sec20"><title>Acridine orange (AO) staining</title><p id="Par48">Acidic and autophagic vacuoles emit red fluorescence when stained with AO stain. Briefly, 0.8–1 × 105 cells were seeded in a six-well plate and treated with siRNA for 48 h. Cells were then allowed to stay for 15 min in serum-free medium containing 1 μg/ml 3,6-bis(dimethylamine) acridine orange and then observed with a Zeiss cell observer microscope. The excitation filter used was 488 nm and the emission filter was 505–530 nm and &gt;650 nm.</p></sec><sec id="Sec21"><title>Hoechst 33342 staining</title><p id="Par49">Following transfection, study the nuclear integrity was determined by using fluorescent Hoechst stains. Cells in a density of 0.8–1 × 10<sup>5</sup> cells were seeded on sterilized cover slips in six-well plates and allowed to attach and grow under standard incubation conditions. This was followed by siRNA treatment 24 h later. After 48 h, the cells were washed once with PBS and fixed by 4% paraformaldehyde for 10 min. Later, the cells were permeabilized with 0.3% Triton X-100 in 1 ml PBS for 10 min, stained with Hoechst 33342 solution, and kept in a dark environment for 10 min. The cells, grown on cover slips, were placed top-down on glass slides and photographed with a fluorescence microscope (350 nm excitation wavelength).</p></sec><sec id="Sec22"><title>Reactive oxygen species measurement</title><p id="Par50">2′,7′–Dichlorofluorescin diacetate (DCFH2-DA) is a cell permeable fluorogenic dye that measures ROS activity within the cell. In short, 0.8–1 × 10<sup>5</sup> cells were seeded in a six-well plate and treated with siRNA for 48 h. A working solution of 10 μM DCFH2-DA was prepared in serum-free media. Cells are washed twice in PBS and incubated for 30 min in the dark with DCFH2-DA. The cells were then washed, harvested and cell pellets suspended in 1 ml PBS. All samples as well as negative and positive controls were subjected to ROS detection using the 488 nm laser for excitation and 535 nm for detection with a BD Accuri C6 flow cytometer.</p></sec><sec id="Sec23"><title>Annexin V assay</title><p id="Par51">The Annexin V-FITC Kit (Biolegend, 640914) and rh Annexin V/APC (Invitrogen, BMS306APC-100) allow detection of apoptotic cells through their affinity to bind to phosphatidylserine residues, which become exposed upon apoptosis and then allow their detection and quantitative determination by fluorescent flow cytometry. The included PI permits labeling of cellular DNA, which is a feature of necrosis when the cellular membrane has been totally compromised. The combined use of both reagents allows the differentiation between three cell populations; i.e., early apoptotic, necrotic, and viable cell populations in response to treatment. Briefly, cells were seeded in a six-well plate, treated by siRNA and harvested following 48 h with EDTA free trypsin (0.25%), then washed once with PBS as well as with 1X binding buffer. The cells were counted and 2*10<sup>5</sup> cells were re-suspended in 100 μl of the 1X binding buffer containing 5 μl Annexin V-FITC per sample. The cells were incubated for 15 min at room temperature in the dark, followed by washing with 1X binding buffer to remove the unbound Annexin V-FITC, and centrifuged. The cell pellets were resuspended in 200 μl of the 1X binding buffer and 5 µl of propidium iodide/sample (provided with the kit) per sample. Analyses were done using flowing software.</p></sec><sec id="Sec24"><title>Statistical analysis</title><p id="Par52">Student’s <italic>t</italic>-test (2 groups) was used to estimate the significance of the group of interest in comparison with a control group for either viability of the cells, colony formation inhibition or increased migration in the siRNA- versus nonsense-treated cells. Graphs and calculations were created using the Graphpad prism version-6 software. <italic>P</italic>-values below 0.05 were considered statistically significant.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>The authors express their gratitude to Dr Ashwini K. Sharma for the generation of Fig. 2-C and his continuous support with questions related to bioinformatics. Doaa M. Ali was supported by a PhD Grant from the Deutscher Akademischer Austauschdienst (DAAD). The authors would like to acknowledge the excellent technical support of the DKFZ Light Microscopy Core Facility (Dr F. Bestvater), the DKFZ FACS Core Facility (Dr S. Schmitt), and the DKFZ Genomics and Proteomics Core Facility (Prof. S. Wiemann). The authors thank the Human Protein Atlas <ext-link xlink:href="https://www.proteinatlas.org/" ext-link-type="url">https://www.proteinatlas.org/</ext-link> as data for optineurin protein expression and survival curve were publically available on their website.</p></ack><sec sec-type="ethics-statement"><sec id="FPar1" sec-type="COI-statement"><title>Conflict of interest</title><p id="Par53">The authors declare that they have no conflict of interest.</p></sec></sec><ref-list id="Bib1"><title>References</title><ref-list><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachaner</surname><given-names>D</given-names></name><name><surname>Genin</surname><given-names>P</given-names></name><name><surname>Laplantine</surname><given-names>E</given-names></name><name><surname>Weil</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Toward an integrative view of Optineurin functions</article-title><source>Cell Cycle</source><year>2012</year><volume>11</volume><fpage>2808</fpage><lpage>2818</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC38XhtlWgtL%2FI</pub-id><pub-id pub-id-type="doi">10.4161/cc.20946</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Yue</surname><given-names>BY</given-names></name></person-group><article-title xml:lang="en">Cellular and molecular biology of optineurin</article-title><source>Int Rev. Cell Mol. Biol.</source><year>2012</year><volume>294</volume><fpage>223</fpage><lpage>258</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC38XhsFKgsLrP</pub-id><pub-id pub-id-type="doi">10.1016/B978-0-12-394305-7.00005-7</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>X</given-names></name><etal/></person-group><article-title xml:lang="en">Processing of optineurin in neuronal cells</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>3618</fpage><lpage>3629</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3MXhtFKkt7k%3D</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M110.175810</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Yue</surname><given-names>BY</given-names></name></person-group><article-title xml:lang="en">Optineurin: the autophagy connection</article-title><source>Exp. Eye Res.</source><year>2016</year><volume>144</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXhtFaiurnO</pub-id><pub-id pub-id-type="doi">10.1016/j.exer.2015.06.029</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turturro</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Shyam</surname><given-names>R</given-names></name><name><surname>Yue</surname><given-names>BY</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">Effects of mutations and deletions in the human optineurin gene</article-title><source>Springer Plus</source><year>2014</year><volume>3</volume><pub-id pub-id-type="doi">10.1186/2193-1801-3-99</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Ohtsubo</surname><given-names>M</given-names></name><name><surname>Hotta</surname><given-names>Y</given-names></name><name><surname>Minoshima</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Oligomerization of optineurin and its oxidative stress- or E50K mutation-driven covalent cross-linking: possible relationship with glaucoma pathology</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0101206</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Marco</surname><given-names>N</given-names></name><name><surname>Buono</surname><given-names>M</given-names></name><name><surname>Troise</surname><given-names>F</given-names></name><name><surname>Diez-Roux</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Optineurin increases cell survival and translocates to the nucleus in a Rab8-dependent manner upon an apoptotic stimulus</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>16147</fpage><lpage>16156</lpage><pub-id pub-id-type="doi">10.1074/jbc.M601467200</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>del Toro</surname><given-names>D</given-names></name><etal/></person-group><article-title xml:lang="en">Mutant huntingtin impairs post-Golgi trafficking to lysosomes by delocalizing optineurin/Rab8 complex from the Golgi apparatus</article-title><source>Mol. Biol. Cell</source><year>2009</year><volume>20</volume><fpage>1478</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1091/mbc.e08-07-0726</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bond</surname><given-names>LM</given-names></name><name><surname>Peden</surname><given-names>AA</given-names></name><name><surname>Kendrick-Jones</surname><given-names>J</given-names></name><name><surname>Sellers</surname><given-names>JR</given-names></name><name><surname>Buss</surname><given-names>F</given-names></name></person-group><article-title xml:lang="en">Myosin VI and its binding partner optineurin are involved in secretory vesicle fusion at the plasma membrane</article-title><source>Mol. Biol. Cell</source><year>2011</year><volume>22</volume><fpage>54</fpage><lpage>65</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3MXhtFGqt7Y%3D</pub-id><pub-id pub-id-type="doi">10.1091/mbc.e10-06-0553</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagabhushana</surname><given-names>A</given-names></name><etal/></person-group><article-title xml:lang="en">Regulation of endocytic trafficking of transferrin receptor by optineurin and its impairment by a glaucoma-associated mutant</article-title><source>BMC Cell Biol.</source><year>2010</year><volume>11</volume><pub-id pub-id-type="doi">10.1186/1471-2121-11-4</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachaner</surname><given-names>D</given-names></name><etal/></person-group><article-title xml:lang="en">Plk1-dependent phosphorylation of optineurin provides a negative feedback mechanism for mitotic progression</article-title><source>Mol. Cell</source><year>2012</year><volume>45</volume><fpage>553</fpage><lpage>566</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC38XjtFWgtrg%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2011.12.030</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachaner</surname><given-names>D</given-names></name><name><surname>Laplantine</surname><given-names>E</given-names></name><name><surname>Genin</surname><given-names>P</given-names></name><name><surname>Weil</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Optineurin: a new vision of cell division control</article-title><source>Cell Cycle</source><year>2012</year><volume>11</volume><fpage>1481</fpage><lpage>1482</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC38XnsVSqsLc%3D</pub-id><pub-id pub-id-type="doi">10.4161/cc.20116</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleason</surname><given-names>CE</given-names></name><name><surname>Ordureau</surname><given-names>A</given-names></name><name><surname>Gourlay</surname><given-names>R</given-names></name><name><surname>Arthur</surname><given-names>JS</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name></person-group><article-title xml:lang="en">Polyubiquitin binding to optineurin is required for optimal activation of TANK-binding kinase 1 and production of interferon beta</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>35663</fpage><lpage>35674</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3MXht1yhtrjM</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M111.267567</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><etal/></person-group><article-title xml:lang="en">Structural insights into the interaction and disease mechanism of neurodegenerative disease-associated optineurin and TBK1 proteins</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XhsFWmsrzM</pub-id><pub-id pub-id-type="doi">10.1038/ncomms12708</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Ishii, R., Nureki, O. <italic>5B83 Crystal structure of Optineurin UBAN in complex with linear ubiquitin</italic> (2016). Available from <ext-link xlink:href="https://www.rcsb.org/structure/5B83" ext-link-type="url">https://www.rcsb.org/structure/5B83</ext-link>.</mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">Linear ubiquitination is involved in the pathogenesis of optineurin-associated amyotrophic lateral sclerosis</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XhsVWmsLrI</pub-id><pub-id pub-id-type="doi">10.1038/ncomms12547</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahlender</surname><given-names>DA</given-names></name><etal/></person-group><article-title xml:lang="en">Optineurin links myosin VI to the Golgi complex and is involved in Golgi organization and exocytosis</article-title><source>J. Cell Biol.</source><year>2005</year><volume>169</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD2MXjslartr0%3D</pub-id><pub-id pub-id-type="doi">10.1083/jcb.200501162</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wild</surname><given-names>P</given-names></name><etal/></person-group><article-title xml:lang="en">Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth</article-title><source>Science</source><year>2011</year><volume>333</volume><fpage>228</fpage><lpage>233</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3MXotlGmtLo%3D</pub-id><pub-id pub-id-type="doi">10.1126/science.1205405</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title xml:lang="en">Ubiquitylation of autophagy receptor Optineurin by HACE1 activates selective autophagy for tumor suppression</article-title><source>Cancer Cell</source><year>2014</year><volume>26</volume><fpage>106</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.05.015</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>YC</given-names></name><name><surname>Holzbaur</surname><given-names>EL</given-names></name></person-group><article-title xml:lang="en">Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>E4439</fpage><lpage>E4448</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXhslSrt73I</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1405752111</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>WC</given-names></name><name><surname>Li</surname><given-names>HY</given-names></name><name><surname>Chen</surname><given-names>GC</given-names></name><name><surname>Chern</surname><given-names>Y</given-names></name><name><surname>Tu</surname><given-names>PH</given-names></name></person-group><article-title xml:lang="en">Mutations in the ubiquitin-binding domain of OPTN/optineurin interfere with autophagy-mediated degradation of misfolded proteins by a dominant-negative mechanism</article-title><source>Autophagy</source><year>2015</year><volume>11</volume><fpage>685</fpage><lpage>700</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXhvFWrur3L</pub-id><pub-id pub-id-type="doi">10.4161/auto.36098</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalasani</surname><given-names>ML</given-names></name><name><surname>Swarup</surname><given-names>G</given-names></name><name><surname>Balasubramanian</surname><given-names>D</given-names></name></person-group><article-title xml:lang="en">Optineurin and its mutants: molecules associated with some forms of glaucoma</article-title><source>Ophthalmic Res.</source><year>2009</year><volume>42</volume><fpage>176</fpage><lpage>184</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD1MXhsFWrsrzM</pub-id><pub-id pub-id-type="doi">10.1159/000232400</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osawa</surname><given-names>T</given-names></name><etal/></person-group><article-title xml:lang="en">Optineurin in neurodegenerative diseases</article-title><source>Neuropathology</source><year>2011</year><volume>31</volume><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1789.2011.01199.x</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>TS</given-names></name><etal/></person-group><article-title xml:lang="en">Optineurin deficiency in mice contributes to impaired cytokine secretion and neutrophil recruitment in bacteria-driven colitis</article-title><source>Dis. Model Mech.</source><year>2015</year><volume>8</volume><fpage>817</fpage><lpage>829</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XhtFCgt7fJ</pub-id><pub-id pub-id-type="doi">10.1242/dmm.020362</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obaid</surname><given-names>R</given-names></name><etal/></person-group><article-title xml:lang="en">Optineurin negatively regulates osteoclast differentiation by modulating NF-kappaB and interferon signaling: implications for Paget’s disease</article-title><source>Cell Rep.</source><year>2015</year><volume>13</volume><fpage>1096</fpage><lpage>1102</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXhslKgsrjL</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2015.09.071</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahib</surname><given-names>L</given-names></name><etal/></person-group><article-title xml:lang="en">Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>2913</fpage><lpage>2921</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXovFalur0%3D</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0155</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamska</surname><given-names>A</given-names></name><name><surname>Domenichini</surname><given-names>A</given-names></name><name><surname>Falasca</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">Pancreatic ductal adenocarcinoma: current and evolving therapies</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><fpage>1338</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.3390/ijms18071338</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loosen</surname><given-names>SH</given-names></name><name><surname>Neumann</surname><given-names>UP</given-names></name><name><surname>Trautwein</surname><given-names>C</given-names></name><name><surname>Roderburg</surname><given-names>C</given-names></name><name><surname>Luedde</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Current and future biomarkers for pancreatic adenocarcinoma</article-title><source>Tumour Biol.</source><year>2017</year><volume>39</volume><fpage>1010428317692231</fpage><pub-id pub-id-type="doi">10.1177/1010428317692231</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrido-Laguna</surname><given-names>I</given-names></name><name><surname>Hidalgo</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">Pancreatic cancer: from state-of-the-art treatments to promising novel therapies</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2015</year><volume>12</volume><fpage>319</fpage><lpage>334</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXlsFersrw%3D</pub-id><pub-id pub-id-type="doi">10.1038/nrclinonc.2015.53</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>BN</given-names></name><name><surname>Olcott</surname><given-names>E</given-names></name><name><surname>Jeffrey</surname><given-names>RB</given-names></name></person-group><article-title xml:lang="en">Extrapancreatic perineural invasion in pancreatic adenocarcinoma</article-title><source>Abdom. Radiol. (NY)</source><year>2018</year><volume>43</volume><fpage>323</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1007/s00261-017-1343-9</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiaravalli</surname><given-names>M</given-names></name><name><surname>Reni</surname><given-names>M</given-names></name><name><surname>O’Reilly</surname><given-names>EM</given-names></name></person-group><article-title xml:lang="en">Pancreatic ductal adenocarcinoma: state-of-the-art 2017 and new therapeutic strategies</article-title><source>Cancer Treat. Rev.</source><year>2017</year><volume>60</volume><fpage>32</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2017.08.007</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Rucki</surname><given-names>AA</given-names></name><name><surname>Che</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma</article-title><source>J. Gastrointest. Oncol.</source><year>2017</year><volume>8</volume><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.21037/jgo.2016.10.02</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>VE</given-names></name><name><surname>Giovannetti</surname><given-names>E</given-names></name><name><surname>Peters</surname><given-names>GJ</given-names></name></person-group><article-title xml:lang="en">Unraveling the complexity of autophagy: potential therapeutic applications in pancreatic ductal adenocarcinoma</article-title><source>Semin. Cancer Biol.</source><year>2015</year><volume>35</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXhsFGhtrfO</pub-id><pub-id pub-id-type="doi">10.1016/j.semcancer.2015.09.011</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">Pancreatic cancers require autophagy for tumor growth</article-title><source>Genes Dev.</source><year>2011</year><volume>25</volume><fpage>717</fpage><lpage>729</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3MXkvFCrtbo%3D</pub-id><pub-id pub-id-type="doi">10.1101/gad.2016111</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>D</given-names></name><etal/></person-group><article-title xml:lang="en">Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs</article-title><source>Eur. J. Cancer</source><year>2014</year><volume>50</volume><fpage>1382</fpage><lpage>1390</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXhvFGku7k%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.ejca.2014.01.011</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Courtesy of Human Protein Atlas. <italic>OPTN. OPTN RNA Expression Overview</italic>. <ext-link xlink:href="https://www.proteinatlas.org/ENSG00000123240-OPTN/pathology" ext-link-type="url">https://www.proteinatlas.org/ENSG00000123240-OPTN/pathology</ext-link> (2016).</mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thul</surname><given-names>Peter J.</given-names></name><name><surname>Åkesson</surname><given-names>Lovisa</given-names></name><name><surname>Wiking</surname><given-names>Mikaela</given-names></name><name><surname>Mahdessian</surname><given-names>Diana</given-names></name><name><surname>Geladaki</surname><given-names>Aikaterini</given-names></name><name><surname>Ait Blal</surname><given-names>Hammou</given-names></name><name><surname>Alm</surname><given-names>Tove</given-names></name><name><surname>Asplund</surname><given-names>Anna</given-names></name><name><surname>Björk</surname><given-names>Lars</given-names></name><name><surname>Breckels</surname><given-names>Lisa M.</given-names></name><name><surname>Bäckström</surname><given-names>Anna</given-names></name><name><surname>Danielsson</surname><given-names>Frida</given-names></name><name><surname>Fagerberg</surname><given-names>Linn</given-names></name><name><surname>Fall</surname><given-names>Jenny</given-names></name><name><surname>Gatto</surname><given-names>Laurent</given-names></name><name><surname>Gnann</surname><given-names>Christian</given-names></name><name><surname>Hober</surname><given-names>Sophia</given-names></name><name><surname>Hjelmare</surname><given-names>Martin</given-names></name><name><surname>Johansson</surname><given-names>Fredric</given-names></name><name><surname>Lee</surname><given-names>Sunjae</given-names></name><name><surname>Lindskog</surname><given-names>Cecilia</given-names></name><name><surname>Mulder</surname><given-names>Jan</given-names></name><name><surname>Mulvey</surname><given-names>Claire M.</given-names></name><name><surname>Nilsson</surname><given-names>Peter</given-names></name><name><surname>Oksvold</surname><given-names>Per</given-names></name><name><surname>Rockberg</surname><given-names>Johan</given-names></name><name><surname>Schutten</surname><given-names>Rutger</given-names></name><name><surname>Schwenk</surname><given-names>Jochen M.</given-names></name><name><surname>Sivertsson</surname><given-names>Åsa</given-names></name><name><surname>Sjöstedt</surname><given-names>Evelina</given-names></name><name><surname>Skogs</surname><given-names>Marie</given-names></name><name><surname>Stadler</surname><given-names>Charlotte</given-names></name><name><surname>Sullivan</surname><given-names>Devin P.</given-names></name><name><surname>Tegel</surname><given-names>Hanna</given-names></name><name><surname>Winsnes</surname><given-names>Casper</given-names></name><name><surname>Zhang</surname><given-names>Cheng</given-names></name><name><surname>Zwahlen</surname><given-names>Martin</given-names></name><name><surname>Mardinoglu</surname><given-names>Adil</given-names></name><name><surname>Pontén</surname><given-names>Fredrik</given-names></name><name><surname>von Feilitzen</surname><given-names>Kalle</given-names></name><name><surname>Lilley</surname><given-names>Kathryn S.</given-names></name><name><surname>Uhlén</surname><given-names>Mathias</given-names></name><name><surname>Lundberg</surname><given-names>Emma</given-names></name></person-group><article-title xml:lang="en">A subcellular map of the human proteome</article-title><source>Science</source><year>2017</year><volume>356</volume><issue>6340</issue><fpage>eaal3321</fpage><pub-id pub-id-type="doi">10.1126/science.aal3321</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlen</surname><given-names>Mathias</given-names></name><name><surname>Zhang</surname><given-names>Cheng</given-names></name><name><surname>Lee</surname><given-names>Sunjae</given-names></name><name><surname>Sjöstedt</surname><given-names>Evelina</given-names></name><name><surname>Fagerberg</surname><given-names>Linn</given-names></name><name><surname>Bidkhori</surname><given-names>Gholamreza</given-names></name><name><surname>Benfeitas</surname><given-names>Rui</given-names></name><name><surname>Arif</surname><given-names>Muhammad</given-names></name><name><surname>Liu</surname><given-names>Zhengtao</given-names></name><name><surname>Edfors</surname><given-names>Fredrik</given-names></name><name><surname>Sanli</surname><given-names>Kemal</given-names></name><name><surname>von Feilitzen</surname><given-names>Kalle</given-names></name><name><surname>Oksvold</surname><given-names>Per</given-names></name><name><surname>Lundberg</surname><given-names>Emma</given-names></name><name><surname>Hober</surname><given-names>Sophia</given-names></name><name><surname>Nilsson</surname><given-names>Peter</given-names></name><name><surname>Mattsson</surname><given-names>Johanna</given-names></name><name><surname>Schwenk</surname><given-names>Jochen M.</given-names></name><name><surname>Brunnström</surname><given-names>Hans</given-names></name><name><surname>Glimelius</surname><given-names>Bengt</given-names></name><name><surname>Sjöblom</surname><given-names>Tobias</given-names></name><name><surname>Edqvist</surname><given-names>Per-Henrik</given-names></name><name><surname>Djureinovic</surname><given-names>Dijana</given-names></name><name><surname>Micke</surname><given-names>Patrick</given-names></name><name><surname>Lindskog</surname><given-names>Cecilia</given-names></name><name><surname>Mardinoglu</surname><given-names>Adil</given-names></name><name><surname>Ponten</surname><given-names>Fredrik</given-names></name></person-group><article-title xml:lang="en">A pathology atlas of the human cancer transcriptome</article-title><source>Science</source><year>2017</year><volume>357</volume><issue>6352</issue><fpage>eaan2507</fpage><pub-id pub-id-type="doi">10.1126/science.aan2507</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Courtesy of Human Protein Atlas. OPTN. <italic>Pancreatic Cancer—Interactive Survival Scatter Plot &amp; Survival Analysis</italic> (2016). Available from <ext-link xlink:href="https://www.proteinatlas.org/ENSG00000123240-OPTN/pathology/tissue/pancreatic+cancer" ext-link-type="url">https://www.proteinatlas.org/ENSG00000123240-OPTN/pathology/tissue/pancreatic+cancer</ext-link>.</mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Klionsky</surname><given-names>DJ</given-names></name></person-group><article-title xml:lang="en">Autophagy and human disease</article-title><source>Cell Cycle</source><year>2007</year><volume>6</volume><fpage>1837</fpage><lpage>1849</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD2sXhtFWmurfM</pub-id><pub-id pub-id-type="doi">10.4161/cc.6.15.4511</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiang</surname><given-names>L</given-names></name><etal/></person-group><article-title xml:lang="en">Regulation of cell proliferation and migration by p62 through stabilization of Twist1</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>9241</fpage><lpage>9246</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXpsVamurs%3D</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1322913111</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>SH</given-names></name><name><surname>Han</surname><given-names>BI</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">Knockout of ATG5 leads to malignant cell transformation and resistance to Src family kinase inhibitor PP2</article-title><source>J. Cell Physiol.</source><year>2018</year><volume>233</volume><fpage>506</fpage><lpage>515</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2sXmvFGjurc%3D</pub-id><pub-id pub-id-type="doi">10.1002/jcp.25912</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><etal/></person-group><article-title xml:lang="en">Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma</article-title><source>Mol. Cancer</source><year>2013</year><volume>12</volume><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3sXhtFKktL7M</pub-id><pub-id pub-id-type="doi">10.1186/1476-4598-12-53</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>ZQ</given-names></name><etal/></person-group><article-title xml:lang="en">BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>31522</fpage><lpage>31543</lpage><pub-id pub-id-type="pmid">26372729</pub-id><pub-id pub-id-type="pmcid">4741622</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><etal/></person-group><article-title xml:lang="en">Lentiviral vector mediated claudin1 silencing inhibits epithelial to mesenchymal transition in breast cancer cells</article-title><source>Viruses</source><year>2015</year><volume>7</volume><fpage>2965</fpage><lpage>2979</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXhsFOhsb3I</pub-id><pub-id pub-id-type="doi">10.3390/v7062755</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name><etal/></person-group><article-title xml:lang="en">CLDN1 Increases drug resistance of non-small cell lung cancer by activating autophagy via upregulation of ULK1 phosphorylation</article-title><source>Med. Sci. Monit.</source><year>2017</year><volume>23</volume><fpage>2906</fpage><lpage>2916</lpage><pub-id pub-id-type="doi">10.12659/MSM.904177</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>C</given-names></name><name><surname>Riedl</surname><given-names>S</given-names></name><name><surname>Ruthnick</surname><given-names>D</given-names></name><name><surname>Notzold</surname><given-names>RR</given-names></name><name><surname>Bauer</surname><given-names>UM</given-names></name></person-group><article-title xml:lang="en">The arginine methyltransferase PRMT6 regulates cell proliferation and senescence through transcriptional repression of tumor suppressor genes</article-title><source>Nucleic Acids Res.</source><year>2012</year><volume>40</volume><fpage>9522</fpage><lpage>9533</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC38XhsFygurfL</pub-id><pub-id pub-id-type="doi">10.1093/nar/gks767</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Brann</surname><given-names>D</given-names></name><name><surname>Vadlamudi</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">PELP1 oncogenic functions involve alternative splicing via PRMT6</article-title><source>Mol. Oncol.</source><year>2014</year><volume>8</volume><fpage>389</fpage><lpage>400</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXhtlKjs7c%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.molonc.2013.12.012</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><etal/></person-group><article-title xml:lang="en">Protein arginine methyltransferase 6 regulates embryonic stem cell identity</article-title><source>Stem Cells Dev.</source><year>2012</year><volume>21</volume><fpage>2613</fpage><lpage>2622</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC38XhtlCqtrjI</pub-id><pub-id pub-id-type="doi">10.1089/scd.2011.0330</pub-id></mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>NH</given-names></name><name><surname>Kim</surname><given-names>SN</given-names></name><name><surname>Seo</surname><given-names>DW</given-names></name><name><surname>Han</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name></person-group><article-title xml:lang="en">PRMT6 overexpression upregulates TSP-1 and downregulates MMPs: its implication in motility and invasion</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2013</year><volume>432</volume><fpage>60</fpage><lpage>65</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3sXislyqtb8%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2013.01.085</pub-id></mixed-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><etal/></person-group><article-title xml:lang="en">Mechanism and biological significance of the overexpression of IFITM3 in gastric cancer</article-title><source>Oncol. Rep.</source><year>2014</year><volume>32</volume><fpage>2648</fpage><lpage>2656</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXitVGktL%2FJ</pub-id><pub-id pub-id-type="doi">10.3892/or.2014.3522</pub-id></mixed-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name></person-group><article-title xml:lang="en">Crosstalk of ER stress-mediated autophagy and ER-phagy: Involvement of UPR and the core autophagy machinery</article-title><source>J. Cell. Physiol.</source><year>2018</year><volume>233</volume><fpage>3867</fpage><lpage>3874</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2sXhsVSgsrfJ</pub-id><pub-id pub-id-type="doi">10.1002/jcp.26137</pub-id><pub-id pub-id-type="pmid">28777470</pub-id></mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rzymski</surname><given-names>T</given-names></name><etal/></person-group><article-title xml:lang="en">Regulation of autophagy by ATF4 in response to severe hypoxia</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><fpage>4424</fpage><lpage>4435</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3cXms1yntbg%3D</pub-id><pub-id pub-id-type="doi">10.1038/onc.2010.191</pub-id></mixed-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rzymski</surname><given-names>T</given-names></name><name><surname>Milani</surname><given-names>M</given-names></name><name><surname>Singleton</surname><given-names>DC</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><article-title xml:lang="en">Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia</article-title><source>Cell Cycle</source><year>2009</year><volume>8</volume><fpage>3838</fpage><lpage>3847</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3cXotlWrtL8%3D</pub-id><pub-id pub-id-type="doi">10.4161/cc.8.23.10086</pub-id></mixed-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>ZY</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Ming</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name></person-group><article-title xml:lang="en">Mitochondrial ROS generation for regulation of autophagic pathways in cancer</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2011</year><volume>414</volume><fpage>5</fpage><lpage>8</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3MXhtlaksL7L</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2011.09.046</pub-id></mixed-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuervo</surname><given-names>AM</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">Chaperone-mediated autophagy: roles in disease and aging</article-title><source>Cell Res.</source><year>2014</year><volume>24</volume><fpage>92</fpage><lpage>104</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3sXhvVOiurjL</pub-id><pub-id pub-id-type="doi">10.1038/cr.2013.153</pub-id></mixed-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Mao</surname><given-names>Z</given-names></name></person-group><article-title xml:lang="en">Signaling and induction of chaperone-mediated autophagy by the endoplasmic reticulum under stress conditions</article-title><source>Autophagy</source><year>2018</year><volume>14</volume><fpage>1094</fpage><lpage>1096</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1cXpslarsL8%3D</pub-id><pub-id pub-id-type="pmid">29771174</pub-id><pub-id pub-id-type="pmcid">6103395</pub-id></mixed-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><etal/></person-group><article-title xml:lang="en">Hsp90 regulates autophagy and plays a role in cancer therapy</article-title><source>Tumour Biol.</source><year>2016</year><volume>37</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-4142-3</pub-id></mixed-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakitani</surname><given-names>K</given-names></name><etal/></person-group><article-title xml:lang="en">Inhibition of autophagy exerts anti-colon cancer effects via apoptosis induced by p53 activation and ER stress</article-title><source>BMC Cancer</source><year>2015</year><volume>15</volume><pub-id pub-id-type="doi">10.1186/s12885-015-1789-5</pub-id></mixed-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title xml:lang="en">Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells</article-title><source>Autophagy</source><year>2016</year><volume>12</volume><fpage>1521</fpage><lpage>1537</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XhtF2hsbjO</pub-id><pub-id pub-id-type="doi">10.1080/15548627.2016.1191722</pub-id></mixed-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><etal/></person-group><article-title xml:lang="en">The switch from ER stress-induced apoptosis to autophagy via ROS-mediated JNK/p62 signals: a survival mechanism in methotrexate-resistant choriocarcinoma cells</article-title><source>Exp. Cell Res.</source><year>2015</year><volume>334</volume><fpage>207</fpage><lpage>218</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXnt1elsLk%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.yexcr.2015.04.010</pub-id></mixed-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlahos</surname><given-names>CJ</given-names></name><name><surname>Matter</surname><given-names>WF</given-names></name><name><surname>Hui</surname><given-names>KY</given-names></name><name><surname>Brown</surname><given-names>RF</given-names></name></person-group><article-title xml:lang="en">A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)</article-title><source>J. Biol. Chem.</source><year>1994</year><volume>269</volume><fpage>5241</fpage><lpage>5248</lpage><pub-id pub-id-type="coi">1:CAS:528:DyaK2cXjtFGit78%3D</pub-id><pub-id pub-id-type="pmid">8106507</pub-id></mixed-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blommaart</surname><given-names>EF</given-names></name><name><surname>Krause</surname><given-names>U</given-names></name><name><surname>Schellens</surname><given-names>JP</given-names></name><name><surname>Vreeling-Sindelarova</surname><given-names>H</given-names></name><name><surname>Meijer</surname><given-names>AJ</given-names></name></person-group><article-title xml:lang="en">The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes</article-title><source>Eur. J. Biochem.</source><year>1997</year><volume>243</volume><fpage>240</fpage><lpage>246</lpage><pub-id pub-id-type="coi">1:CAS:528:DyaK2sXhtVWitL4%3D</pub-id><pub-id pub-id-type="doi">10.1111/j.1432-1033.1997.0240a.x</pub-id></mixed-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>V</given-names></name><name><surname>Zaharieva</surname><given-names>MM</given-names></name><name><surname>Das</surname><given-names>SN</given-names></name><name><surname>Berger</surname><given-names>MR</given-names></name></person-group><article-title xml:lang="en">Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma</article-title><source>Cancer Lett.</source><year>2012</year><volume>319</volume><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC38Xjs1GltLc%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.canlet.2011.12.032</pub-id></mixed-citation></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>SS</given-names></name><etal/></person-group><article-title xml:lang="en">Induction of ER and mitochondrial stress by the alkylphosphocholine erufosine in oral squamous cell carcinoma cells</article-title><source>Cell Death Dis.</source><year>2018</year><volume>9</volume><pub-id pub-id-type="doi">10.1038/s41419-018-0342-2</pub-id></mixed-citation></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaaf</surname><given-names>MB</given-names></name><name><surname>Keulers</surname><given-names>TG</given-names></name><name><surname>Vooijs</surname><given-names>MA</given-names></name><name><surname>Rouschop</surname><given-names>KM</given-names></name></person-group><article-title xml:lang="en">LC3/GABARAP family proteins: autophagy-(un)related functions</article-title><source>FASEB J.</source><year>2016</year><volume>30</volume><fpage>3961</fpage><lpage>3978</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2sXhsVOru7Y%3D</pub-id><pub-id pub-id-type="doi">10.1096/fj.201600698R</pub-id></mixed-citation></ref><ref id="CR67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname><given-names>F</given-names></name><etal/></person-group><article-title xml:lang="en">High-throughput SNP-based authentication of human cell lines</article-title><source>Int J. Cancer</source><year>2013</year><volume>132</volume><fpage>308</fpage><lpage>314</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC38Xpt12rtL8%3D</pub-id><pub-id pub-id-type="doi">10.1002/ijc.27675</pub-id></mixed-citation></ref><ref id="CR68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>SS</given-names></name><name><surname>Akgun</surname><given-names>N</given-names></name><name><surname>Berger</surname><given-names>MR</given-names></name></person-group><article-title xml:lang="en">Erufosine increases RhoB expression in oral squamous carcinoma cells independent of its tumor suppressive mode of action - a short report</article-title><source>Cell Oncol.</source><year>2017</year><volume>40</volume><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XhvVWms7jI</pub-id><pub-id pub-id-type="doi">10.1007/s13402-016-0302-8</pub-id></mixed-citation></ref></ref-list></ref-list><app-group><app id="App1"><sec id="Sec25"><title>Supplementary information</title><p id="Par54"><supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM1_ESM.pdf" mimetype="application" mime-subtype="pdf"><caption xml:lang="en"><p>Supp. Figure 1</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM2_ESM.pdf" mimetype="application" mime-subtype="pdf"><caption xml:lang="en"><p>Supp. Figure 2</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM3_ESM.pdf" mimetype="application" mime-subtype="pdf"><caption xml:lang="en"><p>Supp. Figure 3</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM4_ESM.pdf" mimetype="application" mime-subtype="pdf"><caption xml:lang="en"><p>Supp. Figure 4</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM5_ESM.pdf" mimetype="application" mime-subtype="pdf"><caption xml:lang="en"><p>Supp. Table 1</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM6_ESM.pdf" mimetype="application" mime-subtype="pdf"><caption xml:lang="en"><p>Supp. Table 2</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM7" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM7_ESM.pdf" mimetype="application" mime-subtype="pdf"><caption xml:lang="en"><p>Supp. Table 3</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM8" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM8_ESM.pdf" mimetype="application" mime-subtype="pdf"><caption xml:lang="en"><p>Supp. Table 4</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM9" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM9_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB1</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM10" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM10_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB56</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM11" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM11_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB57</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM12" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM12_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB58</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM13" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM13_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB59</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM14" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM14_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB60</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM15" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM15_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB61</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM16" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM16_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB62</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM17" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM17_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB63</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM18" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM18_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB2</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM19" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM19_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB3</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM20" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM20_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB4</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM21" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM21_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB5</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM22" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM22_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB6</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM23" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM23_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB7</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM24" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM24_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB8</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM25" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM25_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB9</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM26" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM26_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB10</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM27" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM27_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB11</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM28" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM28_ESM.jpg" mimetype="image" mime-subtype="jpeg"><caption xml:lang="en"><p>WB13</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM29" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM29_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB14</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM30" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM30_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB15</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM31" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM31_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB16</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM32" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM32_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB18</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM33" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM33_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB19</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM34" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM34_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB20</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM35" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM35_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB21</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM36" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM36_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB22</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM37" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM37_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB23</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM38" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM38_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB24</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM39" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM39_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB25</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM40" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM40_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB26</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM41" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM41_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB27</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM42" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM42_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB28</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM43" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM43_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB29</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM44" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM44_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB30</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM45" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM45_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB31</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM46" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM46_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB32</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM47" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM47_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB35</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM48" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM48_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB36</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM49" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM49_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB37</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM50" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM50_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB38</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM51" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM51_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB39</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM52" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM52_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB40</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM53" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM53_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB41</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM54" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM54_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB42</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM55" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM55_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB43</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM56" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM56_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB44</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM57" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM57_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB45</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM58" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM58_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB46</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM59" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM59_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB48</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM60" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM60_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB49</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM61" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM61_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB51</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM62" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM62_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB52</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM63" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM63_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB53</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM64" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM64_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB54</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM65" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41420_2019_206_MOESM65_ESM.tif" mimetype="image" mime-subtype="tiff"><caption xml:lang="en"><p>WB55</p></caption></media></supplementary-material></p></sec></app></app-group><notes notes-type="ESMHint"><title>Supplementary information</title><p>The online version of this article (<ext-link xlink:href="https://doi.org/10.1038/s41420-019-0206-2" ext-link-type="doi">https://doi.org/10.1038/s41420-019-0206-2</ext-link>) contains supplementary material, which is available to authorized users.</p></notes><notes notes-type="Misc"><p><bold>Publisher’s note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></notes></back></article></records><facets><facet name="subject"><facet-value count="1">Apoptosis</facet-value><facet-value count="1">Biochemistry, general</facet-value><facet-value count="1">Cell Biology</facet-value><facet-value count="1">Cell Cycle Analysis</facet-value><facet-value count="1">Life Sciences</facet-value><facet-value count="1">Life Sciences, general</facet-value><facet-value count="1">Stem Cells</facet-value></facet><facet name="keyword"/><facet name="pub"><facet-value count="1">Cell Death Discovery</facet-value></facet><facet name="year"><facet-value count="1">2019</facet-value></facet><facet name="country"><facet-value count="1">Egypt</facet-value><facet-value count="1">Germany</facet-value><facet-value count="1">United States</facet-value></facet><facet name="type"><facet-value count="1">Journal</facet-value></facet></facets></response>
